Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma
Yael C Cohen, Albert Oriol, Ka Lung Wu, et al.
Acta Haematologica
|
September 12, 2024
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study
Adrian Duek, Alexandra Tzinman, Kira Maziuk, et al.
Annals of Hematology
|
March 21, 2020
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
Yael C Cohen, Hila Magen, Noa Lavi, et al.
Leukemia Research
|
January 16, 2021
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study
Tamir Shragai, Moshe E Gatt, Adir Shaulov, et al.
American Journal of Hematology
|
October 6, 2015
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia
Yishai Ofran, Ronit Leiba, Chezi Ganzel, et al.
American Journal of Infection Control
|
November 27, 2013
Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial
Ilana Oren, Hannah Sprecher, Renato Finkelstein, et al.
Blood Advances
|
November 27, 2019
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study
Tsila Zuckerman, Ron Ram, Luiza Akria, et al.
Haematologica
|
July 29, 2021
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
Ronit Gurion, Uri Rozovski, Gilad Itchaki, et al.
Leukemia & Lymphoma
|
September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group
Chezi Ganzel, Svetlana Trestman, Shai Levi, et al.
British Journal of Haematology
|
October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
Tamir Shragai, Hila Magen, Noa Lavi, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Clinical Lymphoma, Myeloma & Leukemia
|
January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma
Yael C Cohen, Albert Oriol, Ka Lung Wu, et al.
Acta Haematologica
|
September 12, 2024
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study
Adrian Duek, Alexandra Tzinman, Kira Maziuk, et al.
Annals of Hematology
|
March 21, 2020
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
Yael C Cohen, Hila Magen, Noa Lavi, et al.
Leukemia Research
|
January 16, 2021
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study
Tamir Shragai, Moshe E Gatt, Adir Shaulov, et al.
American Journal of Hematology
|
October 6, 2015
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia
Yishai Ofran, Ronit Leiba, Chezi Ganzel, et al.
American Journal of Infection Control
|
November 27, 2013
Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial
Ilana Oren, Hannah Sprecher, Renato Finkelstein, et al.
Blood Advances
|
November 27, 2019
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study
Tsila Zuckerman, Ron Ram, Luiza Akria, et al.
Haematologica
|
July 29, 2021
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
Ronit Gurion, Uri Rozovski, Gilad Itchaki, et al.
Leukemia & Lymphoma
|
September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group
Chezi Ganzel, Svetlana Trestman, Shai Levi, et al.
British Journal of Haematology
|
October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
Tamir Shragai, Hila Magen, Noa Lavi, et al.
Page
of 6